[1] CLARRETT D M, HACHEM C. Gastroesophageal reflux disease (GERD)[J]. Missouri Med, 2018, 115(3):214-218.
[2] CAI N, FU H J, LIU Z, et al. Advances in the treatment of gastroesophageal reflux disease[J]. Med Graduate J (医学研究生报), 2011, 24(7):771-774.
[3] WANG R, TANG Y P. Progress in etiology and pathogenesis of gastroesophageal reflux disease[J]. Chin J Integr Med Surg (中国中西医结合外科杂志), 2015, 21(2):201-203.
[4] GYAWALI C P, FASS R. Management of gastroesophageal reflux disease[J]. Gastroenterology, 2018, 154(2):302-318.
[5] CHEN J H, ZHONG J, KONG G M, et al. Advances in the treatment of gastroesophageal reflux disease[J]. Chin J Endoscopy (中国内镜杂志), 2015, 21(10):1090-1094.
[6] LU X, PENG G Y. Advances in endoscopic therapy for gastroesophageal reflux disease[J]. Mod Digest Intervent Ther(现代消化及介入诊疗), 2019, 24(12):1361-1373.
[7] JAYNES M, KUMAR A B. The risks of long-term use of proton pump inhibitors:a critical review[J]. Ther Adv Drug Saf, 2018, 10:2042098618809927.
[8] HUO T T, TAO C, YAO F F, et al. Research progress of gastric retention drug delivery system[J]. Chin J New Drugs(中国新药杂志), 2017, 26(4):420-426.
[9] NAMDEV A, JAIN D. Floating drug delivery systems: an emerging trend for the treatment of peptic ulcer[J]. Curr Drug Deliv, 2019, 16(10):874-886.
[10] SATHISH D, HIMABINDU S, KUMAR Y S, et al. Floating drug delivery systems for prolonging gastric residence time:a review[J]. Curr Drug Deliv, 2011, 8(5):494-510.
[11] IBRAHIM H K. A novel liquid effervescent floating delivery system for sustained drug delivery[J]. Drug Discov Ther, 2009, 3(4):168-175.
[12] PRAJAPATI V D, JANI G K, KHUTLIWALA T A, et al. Raft forming system-an upcoming approach of gastroretentive drug delivery system[J]. J Controlled Release, 2013, 168(2):151-165.
[13] ZHANG Y, ZHANG L, ZHANG Q, et al. Enhanced gastric therapeutic effects of Brucea javanica oil and its gastroretentive drug delivery system compared to commercial products in pharmacokinetics study[J]. Drug Des Devel Ther, 2018, 12:535-544.
[14] SINGH B, KAUR A, DHIMAN S, et al. QbD-enabled development of novel stimuli-responsive gastroretentive systems of acyclovir for improved patient compliance and biopharmaceutical performance[J]. AAPS Pharm Sci Tech, 2016, 17(2):454-465.
[15] ALQAHEEM Y, ALOMAIR A, ALHENDI A, et al. Preparation of polyetherimide membrane from non-toxic solvents for the separation of hydrogen from methane[J]. Chem Cent J, 2018, 12(1):80.
[16] YUMEI W, YUANYUAN L, XINYUE L, et al. Research progress of in-situ gelling ophthalmic drug delivery system[J]. Asian J Pharm Sci, 2019, 14(1):1-15,116.
[17] DARGE H F, ANDRGIE A T, TSAI H C, et al. Polysaccharide and polypeptide based injectable thermo-sensitive hydrogels for local biomedical applications[J]. Int J Biol Macromol, 2019, 133:545-563.
[18] HUANG H, QI X, CHEN Y, et al. Thermo-sensitive hydrogels for delivering biotherapeutic molecules: a review[J]. Saudi Pharm J, 2019, 27(7):990-999.
[19] KUMARI B, KHANSILI A, PHOUGAT P, et al. Comprehensive review of the role of acrylic acid derivative polymers in floating drug delivery system[J]. Polim Med, 2019, 49(2):71-79.
[20] JUG M, HAFNER A, LOVRIC J, et al. An overview of in vitro dissolution/release methods for novel mucosal drug delivery systems[J]. J Pharm Biomed Anal, 2018, 147:350-366.
[21] TORT S, HAN D, STECKL A J. Self-inflating floating nanofiber membranes for controlled drug delivery[J]. Int J Pharm, 2020, 579:119164.
[22] STRUGALA V, AVIS J, JOLLIFFE I G, et al. The role of an alginate suspension on pepsin and bile acids-key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease?[J]. J Pharm Pharmacol, 2009, 61(8):1021-1028.
[23] ZHANG M, PANDOLFINO J E, ZHOU X, et al. Assessing different diagnostic tests for gastroesophageal reflux disease: a systematic review and network Meta-analysis[J]. Ther Adv Gastroenterol, 2019, 12:1756284819890537.
[24] ZENTILIN P, IIRITANO E, DULBECCO P, et al. Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a mediterranean diet[J]. Dig Liver Dis, 2006, 38(4):226-232.
[25] MAHMOUD D B, SHUKR M H, ELMESHAD A N. Gastroretentive cosolvent-based in situ gel as a promising approach for simultaneous extended delivery and enhanced bioavailability of mitiglinide calcium[J]. J Pharm Sci, 2019, 108(2):897-906.
[26] IGLESIAS N, GALBIS E, ROMERO-AZOGIL L, et al. In-depth study into polymeric materials in low-density gastroretentive formulations[J]. Pharmaceutics, 2020, 12(7):E636.
[27] KUBO W, KONNO Y, MIYAZAKI S, et al. In situ gelling pectin formulations for oral sustained delivery of paracetamol[J]. Drug Dev Ind Pharm, 2004, 30(6):593-599.
[28] PETCHSOMRIT A, SERMKAEW N, WIWATTANAPATAPEE R. Alginate-based composite sponges as gastroretentive carriers for curcumin-loaded self-microemulsifying drug delivery systems[J]. Sci Pharm, 2017, 85(1):11.
[29] TORNE S R, SHEELA A, SARADA N C. A review on oral liquid as an emerging technology in controlled drug delivery system[J]. Curr Pharm Des, 2018, 24(13):1349-1356.
[30] ZHANG J, LIN H Q, MA Q Y, et al. Advances in the application of sodium alginate and its derivatives in biomedicine[J]. J China Pharm(中国药房), 2019, 30(23):3307-3312.
[31] YEUNG R A, KENNEDY R A. A comparison of selected physico-chemical properties of calcium alginate fibers produced using two different types of sodium alginate[J]. J Mech Behav Biomed Mater, 2019, 90:155-164.
[32] DETTMAR P W, GIL-GONZALEZ D, FISHER J, et al. A comparative study on the raft chemical properties of various alginate antacid raft-forming products[J]. Drug Dev Ind Pharm, 2018, 44(1):30-39.
[33] REIMER C, LODRUP A B, SMITH G, et al. Randomised clinical trial:alginate (gaviscon advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor[J]. Aliment Pharmacol Ther, 2016, 43(8):899-909.
[34] KUMAR J N, PANG V Y T, AIK S X L . Calcium triggered self-assembly of alginate-graft-POEGMA via RAFT for the encapsulation of lipophillic actives[J]. J Mater Chem B, 2017, 5(41):8254-8263.
[35] TYTGAT G N, SIMONEAU G. Clinical and laboratory studies of the antacid and raft-forming properties of rennie alginate suspension[J]. Aliment Pharmacol Ther, 2006, 23(6):759-765.
[36] SWEIS R, KAUFMAN E, ANGGIANSAH A, et al. Post-prandial reflux suppression by a raft-forming alginate (gaviscon advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring:mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients[J]. Aliment Pharmacol Ther, 2013, 37(11):1093-1102.
[37] WILKINSON J, ABD-ELAZIZ K, DAN D I, et al. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (gaviscon double action)[J]. Drug Dev Ind Pharm, 2019, 45(3):430-438.
[38] GARG T, KUMAR A, RATH G, et al. Gastroretentive drug delivery systems for therapeutic management of peptic ulcer[J]. Crit Rev Ther Drug Carrier Syst, 2014, 31(6):531-557.
[39] DERAMAN M A, ABDUL HAFIDZ M I, LAWENKO R M, et al. Randomised clinical trial:the effectiveness of gaviscon advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper[J]. Aliment Pharmacol Ther, 2020, 51(11):1014-1021.
[40] QUARTARONE G. Gastroesophageal reflux in pregnancy:a systematic review on the benefit of raft forming agents[J]. Minerva Ginecol, 2013, 65(5):541-549.
[41] DETTMAR P W, GIL-GONZALEZ D, FISHER J, et al. A comparative study on the raft chemical properties of various alginate antacid raft-forming products[J]. Drug Dev Ind Pharm, 2018, 44(1):30-39.
[42] KAYAL C, SHIPLEY R J, PHILLIPS J B. Physical and mechanical properties of RAFT-stabilised collagen gels for tissue engineering applications[J]. J Mech Behav Biomed Mater, 2019, 99:216-224.
[43] KERDSAKUNDEE N, MAHATTANADUL S, MAHATTANADUL R. Development and evaluation of gastroretentive raft forming systems incorporating curcumin-Eudragit® EPO solid dispersions for gastric ulcer treatment[J]. Eur J Pharm Biopharm, 2015, 94:513-520.
[44] WANNASARIT S, MAHATTANADUL S, ISSARACHOT O, et al. Raft-forming gastro-retentive formulations based on centella asiatica extract-solid dispersions for gastric ulcer treatment[J]. Eur J Pharm Sci, 2020, 143:105204.
[45] BANI-JABER A, ABDULLAH S. Development and characterization of novel ambroxol sustained-release oral suspensions based on drug-polymeric complexation and polymeric raft formation[J]. Pharm Dev Technol, 2020, 25:1-10.
[46] JANG S W, LEE J W, RYU D S, et al. Design of pH-responsive alginate raft formulation of risedronate for reduced esophageal irritation[J]. Int J Biol Macromol, 2014, 70:174-178.
[47] KLEMETSRUD T, KJONIKSEN A L, HIORTH M, et al. Polymer coated liposomes for use in the oral cavity-a study of the in vitro toxicity, effect on cell permeability and interaction with mucin[J]. J Liposome Res, 2018, 28(1):62-73.
[48] BYUN C, ZHENG Y, PIERCE A, et al. The effect of calcium on the cohesive strength and flexural properties of low-methoxyl pectin biopolymers[J]. Molecules, 2019, 25(1):75.
[49] GIACOMAZZA D, BULONE D, SAN BIAGIO P L, et al. The role of sucrose concentration in self-assembly kinetics of high methoxyl pectin[J]. Int J Biol Macromol, 2018, 112:1183-1190.
[50] WASHINGTON N, WILSON C G, GREAVES J L, et al. An investigation into the floating behaviour of a pectincontaining anti-reflux formulation (FF5005) by means of gamma scintigraphy[J]. Scand J Gastroenterol, 1988, 23:920-924.
[51] HAVELUND T, AALYKKE C, RASMUSSEN L. Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease[J]. Eur J Gastroenterol Hepatol, 1997,9(5):509-514.
[52] HAVELUND T, AALYKKE C. The efficacy of a pectin-based raft-forming anti-reflux agent in endoscopy-negative reflux disease[J]. Scand J Gastroenterol, 1997, 32(8):773-777.
[53] WATERHOUSE E T, WASHINGTON C, WASHINGTON N. An investigation into the efficacy of the pectin based anti-reflux formulation-Aflurax[J]. Int J Pharm, 2000, 209(1-2):79-85.
[54] ABOUELATTA S M, ABOELWAFA A A, EL-GAZAYERLY O N. Gastroretentive raft liquid delivery system as a new approach to release extension for carrier-mediated drug[J]. Drug Deliv, 2018, 25(1):1161-1174.
[55] ECCLESTON G, PATERSON R. Gastric raft composition:US, 0063980 [P]. 2005-03-24.
[56] MARCIANI L, LOPEZ-SANCHEZ P, PETTERSSON S, et al. Alginate and HM-pectin in sports-drink give rise to intra-gastric gelation in vivo[J]. Food Funct, 2019, 10(12):7892-7899.
[57] QURESHI D, NAYAK S K, MAJI S, et al. Carrageenan: a wonder polymer from marine algae for potential drug delivery applications[J]. Curr Pharm Des, 2019, 25(11):1172-1186.
[58] SELVAKUMARAN S, MUHAMAD I I, ABD RAZAK S I. Evaluation of kappa carrageenan as potential carrier for floating drug delivery system: effect of pore forming agents[J]. Carbohydr Polym, 2016, 135:207-214.
[59] GASEROD O, ANDERSEN P O, MYRVOLD R, et al. Gelled biopolymer based foam:US, 0137272 [P]. 2005-06-23.
[60] MARIA Y, JORABAR S N, ALAN M S, et al. Raft-forming polysaccharides for the treatment of gastroesophageal reflux disease (GORD): systematic review[J]. J Appl Polymer Sci, 2019, 136(40):48012.
[61] HAH N, GARY S. Strontium-containing complexes for treating gastroesophageal reflux and barrett′s esophagus: US, 0250253 [P]. 2016-09-01.
[62] NAGARWAL R C, SRINATHA A, PANDIT J K. In situ forming formulation:development, evaluation, and optimization using 3(3) factorial design[J]. AAPS Pharm Sci Tech, 2009, 10(3):977-984.
[63] COUTINHO D F, SANT S V, SHIN H, et al. Modified gellan gum hydrogels with tunable physical and mechanical properties[J]. Biomaterials, 2010, 31(29):7494-7502.
[64] ZIA K M, TABASUM S, KHAN M F, et al. Recent trends on gellan gum blends with natural and synthetic polymers: a review[J]. Int J Biol Macromol, 2018, 109:1068-1087.
[65] ZHANG N, LI X, YE J, et al. Effect of gellan gum and xanthan gum synergistic interactions and plasticizers on physical properties of plant-based enteric polymer films[J]. Polymers (Basel), 2020,12(1):121.
[66] ABOU Y N, KASSEM A A, EL-MASSIK M A, et al. Development of gastroretentive metronidazole floating raft system for targeting Helicobacter pylori[J]. Int J Pharm, 2015, 486(1-2):297-305.
[67] PODDAR S, AGARWAL P S, SAHI A K, et al. Fabrication and cytocompatibility evaluation of psyllium husk (isabgol)/gelatin composite scaffolds[J]. Appl Biochem Biotechnol, 2019, 188(3):750-768.
[68] PANDIT A P, POL V V, KULKARNI V S. Xyloglucan based in situ gel of lidocaine HCl for the treatment of periodontosis[J]. J Pharm (Cairo), 2016, 2016:3054321.
[69] KOMOTO D, FURUIKE T, TAMURA H. Preparation of polyelectrolyte complex gel of sodium alginate with chitosan using basic solution of chitosan[J]. Int J Biol Macromol, 2019, 126:54-59.
[70] PACE F, TONINI M, PALLOTTA S, et al. Systematic review:maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken′on demand′[J]. Aliment Pharmacol Ther, 2007, 26:195-204.
[71] FARUP P G, HEIBERT M, HOEG V. Alternative vs. conventional treatment given on-demand for gastroesophageal reflux disease:a randomised controlled trial[J]. BMC Complement Altern Med, 2009, 9:3.